Athena Investment Management’s AbbVie ABBV Stock Holding History

Athena Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28M	Sell	9,063 -2,277	-20%	-$490K	1.35%	16
2026 Q1	$2.47M	Hold	11,340	–	–	1.28%	12
2025 Q4	$2.59M	Sell	11,340 -9	-0.1%	-$2.05K	1.33%	10
2025 Q3	$2.63M	Sell	11,349 -12	-0.1%	-$2.44K	1.37%	9
2025 Q2	$2.11M	Sell	11,361 -25	-0.2%	-$4.65K	1.18%	14
2025 Q1	$2.39M	Hold	11,386	–	–	1.44%	10
2024 Q4	$2.02M	Sell	11,386 -3	-0%	-$552	1.17%	13
2024 Q3	$2.25M	Sell	11,389 -8	-0.1%	-$1.49K	1.28%	11
2024 Q2	$1.95M	Sell	11,397 -30	-0.3%	-$4.97K	1.19%	13
2024 Q1	$2.08M	Sell	11,427 -3	-0%	-$517	1.25%	12
2023 Q4	$1.77M	Sell	11,430 -3	-0%	-$437	1.15%	14
2023 Q3	$1.7M	Sell	11,433 -20	-0.2%	-$2.94K	1.22%	13
2023 Q2	$1.54M	Sell	11,453 -31	-0.3%	-$4.55K	1.06%	16
2023 Q1	$1.83M	Hold	11,484	–	–	1.32%	13
2022 Q4	$1.86M	Buy	11,484 +39	+0.3%	+$5.98K	1.36%	12
2022 Q3	$1.54M	Hold	11,445	–	–	1.29%	14
2022 Q2	$1.75M	Buy	11,445 +159	+1%	+$24.3K	1.38%	12
2022 Q1	$1.83M	Buy	+11,286	New	+$1.64M	1.42%	12

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Athena Investment Management's ABBV Position: Q2 2026 in Review

Athena Investment Management reduced its AbbVie (ABBV) stake by 20% in Q2 2026, selling an estimated $490K and leaving 9,063 shares worth $2.28M. The position accounts for 1.35% of the portfolio, ranked #16.

Athena Investment Management first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.63M in Q3 2025. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Athena Investment Management held 9,063 shares of AbbVie worth $2.28M as of Q2 2026.
Athena Investment Management sold 2,277 AbbVie shares in Q2 2026, an estimated $490K.
AbbVie made up 1.35% of Athena Investment Management's portfolio in Q2 2026, its #16 holding.
Athena Investment Management first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
Athena Investment Management's AbbVie position peaked at $2.63M in Q3 2025.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Athena Investment Management's 13F filing for Q2 2026, filed 6 Aug 2026.